BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tangutoori S, Baldwin P, Sridhar S. PARP inhibitors: A new era of targeted therapy. Maturitas. 2015;81:5-9. [PMID: 25708226 DOI: 10.1016/j.maturitas.2015.01.015] [Cited by in Crossref: 79] [Cited by in F6Publishing: 72] [Article Influence: 13.2] [Reference Citation Analysis]
Number Citing Articles
1 Garufi G, Palazzo A, Paris I, Orlandi A, Cassano A, Tortora G, Scambia G, Bria E, Carbognin L. Neoadjuvant therapy for triple-negative breast cancer: potential predictive biomarkers of activity and efficacy of platinum chemotherapy, PARP- and immune-checkpoint-inhibitors. Expert Opin Pharmacother 2020;21:687-99. [PMID: 32052646 DOI: 10.1080/14656566.2020.1724957] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
2 Kosmidis C, Sapalidis K, Kotidis E, Mixalopoulos N, Zarogoulidis P, Tsavlis D, Baka S, Man YG, Kanellos J. Pancreatic cancer from bench to bedside: molecular pathways and treatment options. Ann Transl Med 2016;4:165. [PMID: 27275478 DOI: 10.21037/atm.2016.05.11] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
3 McQuade RM, Stojanovska V, Bornstein JC, Nurgali K. PARP inhibition in platinum-based chemotherapy: Chemopotentiation and neuroprotection. Pharmacol Res 2018;137:104-13. [PMID: 30278221 DOI: 10.1016/j.phrs.2018.09.031] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
4 Rudolph J, Mahadevan J, Dyer P, Luger K. Poly(ADP-ribose) polymerase 1 searches DNA via a 'monkey bar' mechanism. Elife 2018;7:e37818. [PMID: 30088474 DOI: 10.7554/eLife.37818] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 6.3] [Reference Citation Analysis]
5 Manolis AA, Manolis TA, Mikhailidis DP, Manolis AS. Cardiovascular safety of oncologic agents: a double-edged sword even in the era of targeted therapies - Part 2. Expert Opin Drug Saf 2018;17:893-915. [PMID: 30126303 DOI: 10.1080/14740338.2018.1513489] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
6 Zhou D, Kim SH, Chu W, Voller T, Katzenellenbogen JA. Evaluation of aromatic radiobromination by nucleophilic substitution using diaryliodonium salt precursors. J Labelled Comp Radiopharm 2017;60:450-6. [PMID: 28512784 DOI: 10.1002/jlcr.3519] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
7 Tepedelen BE, Korkmaz M, Tatlisumak E, Uluer ET, Ölmez E, Değerli İ, Soya E, İnan S. A Study on the Anticarcinogenic Effects of Calcium Fructoborate. Biol Trace Elem Res 2017;178:210-7. [PMID: 28028787 DOI: 10.1007/s12011-016-0918-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
8 Li X, Fang T, Xu S, Jin P, Zhou D, Wang Z, Li H, Yang Z, Chen G, Zheng X, Xia Y, Wei X, Zhang Z, Yang X, Wang Y, Gao Q. PARP inhibitors promote stromal fibroblast activation by enhancing CCL5 autocrine signaling in ovarian cancer. NPJ Precis Oncol 2021;5:49. [PMID: 34108603 DOI: 10.1038/s41698-021-00189-w] [Reference Citation Analysis]
9 Zhang Z, Dou X, Yang H, Jia L, Qin K, Gao X, Yang B, Zhang W, Qin C, Zhang F, Shan B. Association of expression of p53, livin, ERCC1, BRCA1 and PARP1 in epithelial ovarian cancer tissue with drug resistance and prognosis. Pathology - Research and Practice 2020;216:152794. [DOI: 10.1016/j.prp.2019.152794] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
10 Glorieux M, Dok R, Nuyts S. Novel DNA targeted therapies for head and neck cancers: clinical potential and biomarkers. Oncotarget 2017;8:81662-78. [PMID: 29113422 DOI: 10.18632/oncotarget.20953] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 6.5] [Reference Citation Analysis]
11 Xie Y, Jiang Y, Yang XB, Wang AQ, Zheng YC, Wan XS, Sang XT, Wang K, Zhang DD, Xu JJ, Li FG, Zhao HT. Response of BRCA1-mutated gallbladder cancer to olaparib: A case report. World J Gastroenterol 2016;22:10254-9. [PMID: 28028375 DOI: 10.3748/wjg.v22.i46.10254] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
12 Cohen PR, Tomson BN, Elkin SK, Marchlik E, Carter JL, Kurzrock R. Genomic portfolio of Merkel cell carcinoma as determined by comprehensive genomic profiling: implications for targeted therapeutics. Oncotarget 2016;7:23454-67. [PMID: 26981779 DOI: 10.18632/oncotarget.8032] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 8.7] [Reference Citation Analysis]
13 Zhang M, Zhang H, Yu Y, Huang H, Li G, Xu C. Synergistic effects of a novel lipid-soluble extract from Pinellia pedatisecta Schott and cisplatin on human cervical carcinoma cell lines through the regulation of DNA damage response signaling pathway. Oncol Lett 2017;13:2121-8. [PMID: 28454371 DOI: 10.3892/ol.2017.5738] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
14 Götting I, Jendrossek V, Matschke J. A New Twist in Protein Kinase B/Akt Signaling: Role of Altered Cancer Cell Metabolism in Akt-Mediated Therapy Resistance. Int J Mol Sci 2020;21:E8563. [PMID: 33202866 DOI: 10.3390/ijms21228563] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
15 Sobot D, Mura S, Couvreur P. How can nanomedicines overcome cellular-based anticancer drug resistance? J Mater Chem B 2016;4:5078-100. [DOI: 10.1039/c6tb00900j] [Cited by in Crossref: 27] [Cited by in F6Publishing: 2] [Article Influence: 5.4] [Reference Citation Analysis]
16 Li L, Karanika S, Yang G, Wang J, Park S, Broom BM, Manyam GC, Wu W, Luo Y, Basourakos S, Song JH, Gallick GE, Karantanos T, Korentzelos D, Azad AK, Kim J, Corn PG, Aparicio AM, Logothetis CJ, Troncoso P, Heffernan T, Toniatti C, Lee HS, Lee JS, Zuo X, Chang W, Yin J, Thompson TC. Androgen receptor inhibitor-induced "BRCAness" and PARP inhibition are synthetically lethal for castration-resistant prostate cancer. Sci Signal 2017;10:eaam7479. [PMID: 28536297 DOI: 10.1126/scisignal.aam7479] [Cited by in Crossref: 80] [Cited by in F6Publishing: 67] [Article Influence: 20.0] [Reference Citation Analysis]
17 Di Marco M, Grassi E, Durante S, Vecchiarelli S, Palloni A, Macchini M, Casadei R, Ricci C, Panzacchi R, Santini D, Biasco G. State of the art biological therapies in pancreatic cancer. World J Gastrointest Oncol 2016;8:55-66. [PMID: 26798437 DOI: 10.4251/wjgo.v8.i1.55] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
18 Incorvaia L, Passiglia F, Rizzo S, Galvano A, Listì A, Barraco N, Maragliano R, Calò V, Natoli C, Ciaccio M, Bazan V, Russo A. "Back to a false normality": new intriguing mechanisms of resistance to PARP inhibitors. Oncotarget 2017;8:23891-904. [PMID: 28055979 DOI: 10.18632/oncotarget.14409] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
19 Abbehausen C. Zinc finger domains as therapeutic targets for metal-based compounds - an update. Metallomics 2019;11:15-28. [PMID: 30303505 DOI: 10.1039/c8mt00262b] [Cited by in Crossref: 28] [Cited by in F6Publishing: 9] [Article Influence: 28.0] [Reference Citation Analysis]
20 Katsogiannou M, Ziouziou H, Karaki S, Andrieu C, Henry de Villeneuve M, Rocchi P. The hallmarks of castration-resistant prostate cancers. Cancer Treat Rev 2015;41:588-97. [PMID: 25981454 DOI: 10.1016/j.ctrv.2015.05.003] [Cited by in Crossref: 65] [Cited by in F6Publishing: 54] [Article Influence: 10.8] [Reference Citation Analysis]
21 Belz JE, Kumar R, Baldwin P, Ojo NC, Leal AS, Royce DB, Zhang D, van de Ven AL, Liby KT, Sridhar S. Sustained Release Talazoparib Implants for Localized Treatment of BRCA1-deficient Breast Cancer. Theranostics 2017;7:4340-9. [PMID: 29158830 DOI: 10.7150/thno.18563] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
22 Wu W, Ma B, Ye H, Wang T, Wang X, Yang J, Wei Y, Zhu J, Chen L. Millepachine, a potential topoisomerase II inhibitor induces apoptosis via activation of NF-κB pathway in ovarian cancer. Oncotarget 2016;7:52281-93. [PMID: 27447570 DOI: 10.18632/oncotarget.10739] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
23 Kim Y, Kim A, Sharip A, Sharip A, Jiang J, Yang Q, Xie Y. Reverse the Resistance to PARP Inhibitors. Int J Biol Sci 2017;13:198-208. [PMID: 28255272 DOI: 10.7150/ijbs.17240] [Cited by in Crossref: 44] [Cited by in F6Publishing: 37] [Article Influence: 11.0] [Reference Citation Analysis]
24 Ma Y, He L, Huang Q, Zheng S, Zhang Z, Li H, Liu S. Response to olaparib in metastatic castration-resistant prostate cancer with germline BRCA2 mutation: a case report. BMC Med Genet 2018;19:185. [PMID: 30333000 DOI: 10.1186/s12881-018-0703-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
25 Nizialek E, Antonarakis ES. PARP Inhibitors in Metastatic Prostate Cancer: Evidence to Date. Cancer Manag Res 2020;12:8105-14. [PMID: 32982407 DOI: 10.2147/CMAR.S227033] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 13.0] [Reference Citation Analysis]
26 Wang Y, Chen Q, Wu D, Chen Q, Gong G, He L, Wu X. Lamin-A interacting protein Hsp90 is required for DNA damage repair and chemoresistance of ovarian cancer cells. Cell Death Dis 2021;12:786. [PMID: 34381017 DOI: 10.1038/s41419-021-04074-z] [Reference Citation Analysis]
27 Lim HJ, Ledger W. Targeted therapy in ovarian cancer. Womens Health (Lond) 2016;12:363-78. [PMID: 27215391 DOI: 10.2217/whe.16.4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
28 Jannetti SA, Zeglis BM, Zalutsky MR, Reiner T. Poly(ADP-Ribose)Polymerase (PARP) Inhibitors and Radiation Therapy. Front Pharmacol 2020;11:170. [PMID: 32194409 DOI: 10.3389/fphar.2020.00170] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 15.0] [Reference Citation Analysis]
29 Bogliolo S, Cassani C, Dominoni M, Musacchi V, Venturini PL, Spinillo A, Ferrero S, Gardella B. Veliparib for the treatment of ovarian cancer. Expert Opin Investig Drugs 2016;25:367-74. [PMID: 26807493 DOI: 10.1517/13543784.2016.1146677] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
30 Dufour R, Daumar P, Mounetou E, Aubel C, Kwiatkowski F, Abrial C, Vatoux C, Penault-Llorca F, Bamdad M. BCRP and P-gp relay overexpression in triple negative basal-like breast cancer cell line: a prospective role in resistance to Olaparib. Sci Rep 2015;5:12670. [PMID: 26234720 DOI: 10.1038/srep12670] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
31 OʼSullivan Coyne G, Chen A, Kummar S. Delivering on the promise: poly ADP ribose polymerase inhibition as targeted anticancer therapy. Curr Opin Oncol 2015;27:475-81. [PMID: 26447876 DOI: 10.1097/CCO.0000000000000238] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
32 Sahu B, Narota A, Naura AS. Pharmacological inhibition of poly (ADP-ribose) polymerase by olaparib, prevents acute lung injury associated cognitive deficits potentially through suppression of inflammatory response. Eur J Pharmacol 2020;877:173091. [PMID: 32234526 DOI: 10.1016/j.ejphar.2020.173091] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
33 Fernandez A, O'Leary C, O'Byrne KJ, Burgess J, Richard DJ, Suraweera A. Epigenetic Mechanisms in DNA Double Strand Break Repair: A Clinical Review. Front Mol Biosci 2021;8:685440. [PMID: 34307454 DOI: 10.3389/fmolb.2021.685440] [Reference Citation Analysis]
34 Murata S, Zhang C, Finch N, Zhang K, Campo L, Breuer EK. Predictors and Modulators of Synthetic Lethality: An Update on PARP Inhibitors and Personalized Medicine. Biomed Res Int 2016;2016:2346585. [PMID: 27642590 DOI: 10.1155/2016/2346585] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
35 Singh B, Yang S, Krishna A, Sridhar S. Nanoparticle Formulations of Poly (ADP-ribose) Polymerase Inhibitors for Cancer Therapy. Front Chem 2020;8:594619. [PMID: 33330383 DOI: 10.3389/fchem.2020.594619] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
36 Hu Z, Mi S, Zhao T, Peng C, Peng Y, Chen L, Zhu W, Yao Y, Song Q, Li X, Li X, Jia C, Pei H. BGL3 lncRNA mediates retention of the BRCA1/BARD1 complex at DNA damage sites. EMBO J 2020;39:e104133. [PMID: 32347575 DOI: 10.15252/embj.2019104133] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
37 Quiñonero F, Mesas C, Doello K, Cabeza L, Perazzoli G, Jimenez-Luna C, Rama AR, Melguizo C, Prados J. The challenge of drug resistance in pancreatic ductal adenocarcinoma: a current overview. Cancer Biol Med 2019;16:688-99. [PMID: 31908888 DOI: 10.20892/j.issn.2095-3941.2019.0252] [Cited by in F6Publishing: 12] [Reference Citation Analysis]
38 Zhu Z. Miltirone-induced apoptosis in cisplatin-resistant lung cancer cells through upregulation of p53 signaling pathways. Oncol Lett 2018;15:8841-6. [PMID: 29928326 DOI: 10.3892/ol.2018.8440] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
39 Fitzgerald TL, Lertpiriyapong K, Cocco L, Martelli AM, Libra M, Candido S, Montalto G, Cervello M, Steelman L, Abrams SL, McCubrey JA. Roles of EGFR and KRAS and their downstream signaling pathways in pancreatic cancer and pancreatic cancer stem cells. Adv Biol Regul 2015;59:65-81. [PMID: 26257206 DOI: 10.1016/j.jbior.2015.06.003] [Cited by in Crossref: 85] [Cited by in F6Publishing: 73] [Article Influence: 14.2] [Reference Citation Analysis]
40 Brochier C, Jones JI, Willis DE, Langley B. Poly(ADP-ribose) polymerase 1 is a novel target to promote axonal regeneration. Proc Natl Acad Sci U S A 2015;112:15220-5. [PMID: 26598704 DOI: 10.1073/pnas.1509754112] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
41 Hirai T, Saito S, Fujimori H, Matsushita K, Nishio T, Okayasu R, Masutani M. Radiosensitization by PARP inhibition to proton beam irradiation in cancer cells. Biochem Biophys Res Commun 2016;478:234-40. [PMID: 27425251 DOI: 10.1016/j.bbrc.2016.07.062] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 4.6] [Reference Citation Analysis]
42 Benstead-Hume G, Chen X, Hopkins SR, Lane KA, Downs JA, Pearl FMG. Predicting synthetic lethal interactions using conserved patterns in protein interaction networks. PLoS Comput Biol 2019;15:e1006888. [PMID: 30995217 DOI: 10.1371/journal.pcbi.1006888] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 7.5] [Reference Citation Analysis]
43 Sharma HS, Muresanu DF, Castellani RJ, Nozari A, Lafuente JV, Tian ZR, Sahib S, Bryukhovetskiy I, Bryukhovetskiy A, Buzoianu AD, Patnaik R, Wiklund L, Sharma A. Pathophysiology of blood-brain barrier in brain tumor. Novel therapeutic advances using nanomedicine. Int Rev Neurobiol 2020;151:1-66. [PMID: 32448602 DOI: 10.1016/bs.irn.2020.03.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
44 Schild SE, Vokes EE. Pathways to improving combined modality therapy for stage III nonsmall-cell lung cancer. Ann Oncol 2016;27:590-9. [PMID: 26712904 DOI: 10.1093/annonc/mdv621] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 3.7] [Reference Citation Analysis]
45 Zhou Y, Liu L, Tao S, Yao Y, Wang Y, Wei Q, Shao A, Deng Y. Parthanatos and its associated components: Promising therapeutic targets for cancer. Pharmacol Res 2021;163:105299. [PMID: 33171306 DOI: 10.1016/j.phrs.2020.105299] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
46 Zhong Y, Meng Y, Xu X, Zhao L, Li Z, You Q, Bian J. Design, synthesis and evaluation of phthalazinone thiohydantoin-based derivative as potent PARP-1 inhibitors. Bioorganic Chemistry 2019;91:103181. [DOI: 10.1016/j.bioorg.2019.103181] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
47 Pacenta HL, Allen-Rhoades W, Langenau D, Houghton PJ, Keller C, Heske CM, Deel MD, Linardic CM, Shern JF, Stewart E, Turpin B, Harrison DJ, Khan J, Mascarenhas L, Skapek SX, Meyer WH, Hawkins DS, Chen EY, Amatruda JF, Hingorani P, Laetsch TW. Prioritization of Novel Agents for Patients with Rhabdomyosarcoma: A Report from the Children's Oncology Group (COG) New Agents for Rhabdomyosarcoma Task Force. J Clin Med 2021;10:1416. [PMID: 33915882 DOI: 10.3390/jcm10071416] [Reference Citation Analysis]
48 Sermijn E, Delesie L, Deschepper E, Pauwels I, Bonduelle M, Teugels E, De Grève J. The impact of an interventional counselling procedure in families with a BRCA1/2 gene mutation: efficacy and safety. Fam Cancer 2016;15:155-62. [PMID: 26748927 DOI: 10.1007/s10689-015-9854-4] [Cited by in Crossref: 31] [Cited by in F6Publishing: 20] [Article Influence: 6.2] [Reference Citation Analysis]
49 Lawrence LM, Russell R, Denning CE, Zgheib NB, Salisbury T, Lirette ST, Valluri J, Claudio PP, Denning KL. Expression of poly-ADP-ribose polymerase (PARP) in endometrial adenocarcinoma: Prognostic potential. Pathol Res Pract 2020;216:152965. [PMID: 32360251 DOI: 10.1016/j.prp.2020.152965] [Reference Citation Analysis]
50 Baptista SJ, Silva MM, Moroni E, Meli M, Colombo G, Dinis TC, Salvador JA. Novel PARP-1 Inhibitor Scaffolds Disclosed by a Dynamic Structure-Based Pharmacophore Approach. PLoS One 2017;12:e0170846. [PMID: 28122037 DOI: 10.1371/journal.pone.0170846] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
51 Tang L, Wu W, Zhang C, Shi Z, Chen D, Zhai X, Jiang Y. Discovery of the PARP (poly ADP-ribose polymerase) inhibitor 2-(1-(4,4-difluorocyclohexyl)piperidin-4-yl)-1H-benzo[d]imidazole-4-carboxamide for the treatment of cancer. Bioorg Chem 2021;114:105026. [PMID: 34186467 DOI: 10.1016/j.bioorg.2021.105026] [Reference Citation Analysis]
52 Cerrato A, Morra F, Celetti A. Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic. J Exp Clin Cancer Res 2016;35:179. [PMID: 27884198 DOI: 10.1186/s13046-016-0456-2] [Cited by in Crossref: 56] [Cited by in F6Publishing: 46] [Article Influence: 11.2] [Reference Citation Analysis]
53 Martin GA, Chen AH, Parikh K. A Novel Use of Olaparib for the Treatment of Metastatic Castration-Recurrent Prostate Cancer. Pharmacotherapy 2017;37:1406-14. [PMID: 28895177 DOI: 10.1002/phar.2027] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 4.7] [Reference Citation Analysis]
54 Neufeld MJ, Duross AN, Landry MR, Winter H, Goforth AM, Sun C. Co-delivery of PARP and PI3K inhibitors by nanoscale metal–organic frameworks for enhanced tumor chemoradiation. Nano Res 2019;12:3003-17. [DOI: 10.1007/s12274-019-2544-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 6.5] [Reference Citation Analysis]
55 Karanikas M, Esempidis A, Chasan ZT, Deftereou T, Antonopoulou M, Bozali F, Amarantidis K, Man YG. Pancreatic Cancer from Molecular Pathways to Treatment Opinion. J Cancer 2016;7:1328-39. [PMID: 27390608 DOI: 10.7150/jca.15419] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
56 Degterev A, Linkermann A. Generation of small molecules to interfere with regulated necrosis. Cell Mol Life Sci 2016;73:2251-67. [PMID: 27048812 DOI: 10.1007/s00018-016-2198-x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 8.8] [Reference Citation Analysis]
57 Kocik J, Machula M, Wisniewska A, Surmiak E, Holak TA, Skalniak L. Helping the Released Guardian: Drug Combinations for Supporting the Anticancer Activity of HDM2 (MDM2) Antagonists. Cancers (Basel) 2019;11:E1014. [PMID: 31331108 DOI: 10.3390/cancers11071014] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 6.5] [Reference Citation Analysis]
58 Benstead-Hume G, Wooller SK, Pearl FMG. Computational Approaches to Identify Genetic Interactions for Cancer Therapeutics. J Integr Bioinform 2017;14:/j/jib. [PMID: 28941356 DOI: 10.1515/jib-2017-0027] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
59 Passeri D, Camaioni E, Liscio P, Sabbatini P, Ferri M, Carotti A, Giacchè N, Pellicciari R, Gioiello A, Macchiarulo A. Concepts and Molecular Aspects in the Polypharmacology of PARP-1 Inhibitors. ChemMedChem 2016;11:1219-26. [PMID: 26424664 DOI: 10.1002/cmdc.201500391] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
60 Silva AP, Coelho PV, Anazetti M, Simioni PU. Targeted therapies for the treatment of non-small-cell lung cancer: Monoclonal antibodies and biological inhibitors. Hum Vaccin Immunother 2017;13:843-53. [PMID: 27831000 DOI: 10.1080/21645515.2016.1249551] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 5.6] [Reference Citation Analysis]
61 Ganguly B, Dolfi SC, Rodriguez-Rodriguez L, Ganesan S, Hirshfield KM. Role of Biomarkers in the Development of PARP Inhibitors. Biomark Cancer 2016;8:15-25. [PMID: 26997874 DOI: 10.4137/BIC.S36679] [Cited by in Crossref: 9] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
62 Daumar P, Dufour R, Dubois C, Penault-llorca F, Bamdad M, Mounetou E. Development and validation of a high-performance liquid chromatography method for the quantitation of intracellular PARP inhibitor Olaparib in cancer cells. Journal of Pharmaceutical and Biomedical Analysis 2018;152:74-80. [DOI: 10.1016/j.jpba.2018.01.036] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 3.3] [Reference Citation Analysis]
63 Bartolomei G, Leutert M, Manzo M, Baubec T, Hottiger MO. Analysis of Chromatin ADP-Ribosylation at the Genome-wide Level and at Specific Loci by ADPr-ChAP. Mol Cell 2016;61:474-85. [PMID: 26833088 DOI: 10.1016/j.molcel.2015.12.025] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 6.0] [Reference Citation Analysis]
64 Martínez-Bosch N, Fernández-Zapico ME, Navarro P, Yélamos J. Poly(ADP-Ribose) Polymerases: New Players in the Pathogenesis of Exocrine Pancreatic Diseases. Am J Pathol 2016;186:234-41. [PMID: 26687988 DOI: 10.1016/j.ajpath.2015.09.021] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
65 Kraus WL. PARPs and ADP-Ribosylation: 50 Years … and Counting. Mol Cell 2015;58:902-10. [PMID: 26091339 DOI: 10.1016/j.molcel.2015.06.006] [Cited by in Crossref: 92] [Cited by in F6Publishing: 77] [Article Influence: 15.3] [Reference Citation Analysis]
66 Green TM, Alpaugh ML, Barsky SH, Rappa G, Lorico A. Breast Cancer-Derived Extracellular Vesicles: Characterization and Contribution to the Metastatic Phenotype. Biomed Res Int 2015;2015:634865. [PMID: 26601108 DOI: 10.1155/2015/634865] [Cited by in Crossref: 28] [Cited by in F6Publishing: 32] [Article Influence: 4.7] [Reference Citation Analysis]
67 Liao H, Lee C, Hsiao P, Chen Y, Tseng C, Tzeng C, Chen Y, Chen J, Chang Y, Chang J. TCH1036, a indeno[1,2-c]quinoline derivative, potentially inhibited the growth of human brain malignant glioma (GBM) 8401 cells via suppression of the expression of Suv39h1 and PARP. Biomedicine & Pharmacotherapy 2016;82:649-59. [DOI: 10.1016/j.biopha.2016.06.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
68 Zhang W, van Gent DC, Incrocci L, van Weerden WM, Nonnekens J. Role of the DNA damage response in prostate cancer formation, progression and treatment. Prostate Cancer Prostatic Dis 2020;23:24-37. [PMID: 31197228 DOI: 10.1038/s41391-019-0153-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
69 Yuan Z, Chen S, Sun Q, Wang N, Li D, Miao S, Gao C, Chen Y, Tan C, Jiang Y. Olaparib hydroxamic acid derivatives as dual PARP and HDAC inhibitors for cancer therapy. Bioorganic & Medicinal Chemistry 2017;25:4100-9. [DOI: 10.1016/j.bmc.2017.05.058] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 8.0] [Reference Citation Analysis]
70 Torgovnick A, Schumacher B. DNA repair mechanisms in cancer development and therapy. Front Genet 2015;6:157. [PMID: 25954303 DOI: 10.3389/fgene.2015.00157] [Cited by in Crossref: 126] [Cited by in F6Publishing: 102] [Article Influence: 21.0] [Reference Citation Analysis]
71 Gray PN, Dunlop CL, Elliott AM. Not All Next Generation Sequencing Diagnostics are Created Equal: Understanding the Nuances of Solid Tumor Assay Design for Somatic Mutation Detection. Cancers (Basel) 2015;7:1313-32. [PMID: 26193321 DOI: 10.3390/cancers7030837] [Cited by in Crossref: 39] [Cited by in F6Publishing: 27] [Article Influence: 6.5] [Reference Citation Analysis]
72 Anuchina AA, Lavrov AV, Smirnikhina SA. TIRR: a potential front runner in HDR race−hypotheses and perspectives. Mol Biol Rep 2020;47:2371-9. [DOI: 10.1007/s11033-020-05285-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]